Crk-L activators are a class of chemicals that target the Crk-like protein (Crk-L), which is a member of the Crk family of adaptor proteins. These proteins are characterized by their non-enzymatic role in intracellular signaling pathways and are crucial for facilitating interactions between various proteins, thereby influencing cellular processes. The Crk-L protein contains specific domains, such as the SH2 and SH3 domains, which allow it to bind to phosphorylated tyrosine residues and proline-rich motifs on other proteins, respectively. By modulating the activity of Crk-L, Crk-L activators can affect the assembly of protein complexes that are essential for signal transduction. The precise regulation of Crk-L activity is of great interest given its involvement in a wide range of cellular events, including the reorganization of the cytoskeleton, cell migration, and the regulation of gene expression.
The development of Crk-L activators is grounded in the understanding of the structure and interaction dynamics of the Crk-L protein. Crk-L activators are designed to enhance the protein's natural function without altering its expression level. This is achieved by promoting the interaction between Crk-L and its binding partners or by stabilizing the active conformation of Crk-L, allowing it to more efficiently participate in signaling pathways. The activators may bind directly to the functional domains of Crk-L, mimicking the natural ligands, or they may interact with upstream or downstream elements within the signaling cascade to indirectly augment Crk-L activity. Through the modulation of Crk-L, these activators can influence the intricate network of signaling pathways in which Crk-L is a critical component, thereby affecting the overall behavior of the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PP1 Analog II, 1NM-PP1 | 221244-14-0 | sc-203214 sc-203214A | 1 mg 5 mg | $106.00 $530.00 | 10 | |
PP1 activates Crk-L by inhibiting Src family kinases. Src inhibition enhances Crk-L activity, modulating downstream signaling pathways involved in cell adhesion and migration. | ||||||
EHop-016 | 1380432-32-5 | sc-497382 | 5 mg | $80.00 | ||
EHop-016 activates Crk-L by inhibiting Rac1. Rac1 inhibition enhances Crk-L-mediated cellular processes, including cytoskeletal rearrangement and migration. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib activates Crk-L by inhibiting Abl kinase. Abl inhibition enhances Crk-L activity, influencing cellular adhesion and migration. | ||||||
Bcr-abl Inhibitor | 778270-11-4 | sc-203836 | 5 mg | $149.00 | 1 | |
GNF 2 activates Crk-L by inhibiting Abl kinase. Abl inhibition enhances Crk-L activity, influencing cellular adhesion and migration. | ||||||